IDD : Institute For Diabetes Discovery

Insulin resistance (IR) is a key metabolic defect in type 2 diabetes. Insulin resistance is a condition in which the cells of the body become resistant to the effects of insulin, that is, the normal response to a given amount of insulin is reduced. As a result, higher levels of insulin are needed in order for insulin to have its effects. This compensatory state of hyperinsulinemia (high insulin levels in the blood) is felt to be a marker for IR. The development of type 2 diabetes occurs when the pancreas fails to sustain this increase insulin secretion.

Inhibition of Protein Tyrosine Phosphatase 1b

IDD has focused on the insulin signal-transduction pathway to improve insulin sensitivity. Scientists have developed orally available protein tyrosine phosphatase PTP 1b inhibitors that effectively treat insulin resistance in vivo. In addition, these compounds reduce hyperinsulinemia, an independent risk factor for heart disease. They may also be beneficial for obese individuals at risk for developing diabetes.

Novel Targets

IDD is building on the expertise of our scientists by identifying other novel targets to address insulin resistance.

View Diabetic Atherosclerosis Research Focus
View More IDD Publications

| IDD 676 | | Glycation | | Obesity | | Insulin Resistance | | Diabetic Atherosclerosis |